Flufenamic acid-d4

CAT:
804-HY-B1221S
Size:
500 µg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Flufenamic acid-d4 - image 1

Flufenamic acid-d4

  • UNSPSC Description:

    Flufenamic acid-d4 is deuterium labeled Flufenamic acid. Flufenamic acid is a non-steroidal anti-inflammatory agent, inhibits cyclooxygenase (COX), activates AMPK, and also modulates ion channels, blocking chloride channels and L-type Ca2+ channels, modulating non-selective cation channels (NSC), activating K+ channels. Flufenamic acid binds to the central pocket of TEAD2 YBD and inhibits both TEAD function and TEAD-YAP-dependent processes, such as cell migration and proliferation.
  • Target Antigen:

    AMPK; Calcium Channel; Chloride Channel; COX; Isotope-Labeled Compounds; Parasite; Potassium Channel
  • Type:

    Isotope-Labeled Compounds
  • Related Pathways:

    Anti-infection;Epigenetics;Immunology/Inflammation;Membrane Transporter/Ion Channel;Neuronal Signaling;Others;PI3K/Akt/mTOR
  • Applications:

    COVID-19-immunoregulation
  • Field of Research:

    Inflammation/Immunology
  • Solubility:

    10 mM in DMSO
  • Smiles:

    OC(C(C([2H])=C([2H])C([2H])=C1[2H])=C1NC2=CC(C(F)(F)F)=CC=C2)=O
  • Molecular Weight:

    285.25
  • References & Citations:

    [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.|[2]Guinamard R, et al. Flufenamic acid as an ion channel modulator. Pharmacol Ther. 2013 May;138(2):272-84.|[3]Pobbati AV, et al. Targeting the Central Pocket in Human Transcription Factor TEAD as a Potential Cancer Therapeutic Strategy. Structure. 2015;23(11):2076-2086.|[4]Pongkorpsakol P, et al. Cellular mechanisms underlying the inhibitory effect of flufenamic acid on chloride secretion in human intestinal epithelial cells. J Pharmacol Sci. 2017 Jun;134(2):93-100.|[5]Pongkorpsakol P, et al. Flufenamic acid protects against intestinal fluid secretion and barrier leakage in a mouse model of Vibrio cholerae infection through NF-κB inhibition and AMPK activation. Eur J Pharmacol. 2017 Mar 5;798:94-104.
  • Shipping Conditions:

    Room temperature
  • Clinical Information:

    No Development Reported
  • CAS Number:

    1185071-99-1